Aripiprazole Tablet
Product Images NDC 71335-1903

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 71335-1903). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazole-fig-16.jpg (Aripiprazole Fig 16)

A line graph comparing the proportion of subjects with relapse over days from randomization between Aripiprazole and placebo groups. The x-axis shows days from randomization, and the y-axis shows the proportion with relapse. A solid blue line represents Aripiprazole, and a dashed red line represents placebo, with both groups' subject counts at risk noted below the x-axis.*

FDA Label Image

Aripiprazole-fig-17 (Aripiprazole Fig 17)

A line graph depicting the proportion with relapse over days from randomization for study subjects treated with Aripiprazole versus placebo. The x-axis shows days from 0 to 364, with numbers of subjects at risk listed below. The y-axis shows the proportion with relapse from 0.0 to 1.0. The Aripiprazole group is represented by a solid line and the placebo group by a dashed line, indicating lower relapse proportion for Aripiprazole over time.*

FDA Label Image

Effects Of Other Drugs On Dehydro-aripiprazole (Aripiprazole Fig10)

A pharmacokinetic chart depicting the fold change and 90% confidence intervals for dehydro-aripiprazole levels in the presence of various interacting drugs. The x-axis shows change relative to reference without interacting drug, ranging from 0.5 to 3. Drugs are grouped as CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and others, with values for AUC and Cmax changes.*

FDA Label Image

Effects Of Aripiprazole On Pharmacokinetics Of Other Drugs (Aripiprazole Fig11)

A forest plot showing the fold change and 90% confidence intervals for pharmacokinetic parameters such as AUC and Cmax, as well as INR, for various drugs including dextromethorphan, warfarin (S- and R- isomers), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, O-desmethylvenlafaxine, and escitalopram, relative to a reference without an interacting drug.*

FDA Label Image

Effects Of Intrinsic Factors On Aripiprazole (Aripiprazole Fig12)

A pharmacokinetic chart showing the fold change and 90% confidence intervals for Aripiprazole under various conditions, including CYP2D6 metabolism status, gender, age groups, hepatic impairment severity, and severe renal impairment. The x-axis represents change relative to reference, while the y-axis distinguishes AUC and Cmax parameters for each condition.*

FDA Label Image

Effects Of Intrinsic Factors On Dehydro-aripiprazole (Aripiprazole Fig13)

A pharmacokinetic chart displaying Dehydro-Aripiprazole fold change with 90% confidence intervals across various factors including CYP2D6 metabolism status, gender, age groups, hepatic impairment levels, and severe renal impairment. The x-axis shows change relative to a reference value for AUC and Cmax parameters.*

FDA Label Image

Effects Of Other Drugs On Aripiprazole (Aripiprazole Fig9)

A pharmacokinetic chart depicting the fold change and 90% confidence intervals for Aripiprazole's AUC and Cmax relative to a reference without interacting drugs. The chart compares the effects of CYP3A4 inhibitors and inducers, CYP2D6 inhibitors, gastric acid blockers, and other drugs on Aripiprazole's exposure.*

FDA Label Image

Aripiprazole Structure (Aripiprazole Fig8)

Chemical structure diagram of Aripiprazole, showing its molecular framework with chlorine atoms attached to the aromatic ring and a piperazine moiety linked by an ether chain to a quinolinone structure.*

FDA Label Image

Aripiprazole-graph (Aripiprazole Graph)

A Kaplan-Meier survival curve graph showing the proportion of subjects with relapse over days from randomization for Aripiprazole 10 mg tablets versus placebo. The x-axis represents days from randomization up to 182 days, and the y-axis indicates the proportion with relapse. The chart includes the number of subjects at risk at various time points for both groups.*

FDA Label Image

Label (Lbl713351903)

Label for Aripiprazole 10 mg tablet packaged by Bryant Ranch Prepack. The label notes comparison to Abilify 10 mg tablet by Alkem Laboratories Limited, includes storage instructions at 20°-25°C (68°-77°F), and a caution to keep drugs out of reach of children. The NDC number 71335-1903 is displayed, along with lot and barcode information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.